Debrecen

• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 5 2024-06-07 Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressi … Recruiting
  2022-502783-21-00 5 2024-02-20 B-Cell Non-Hodgkin's Lymphoma
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-505121-14-00 5 2024-01-18 Moderate to Severe Plaque Psoriasis
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 5 2023-11-16 Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
• Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerati … Recruiting
  2022-501788-41-00 5 2023-11-14 Ulcerative Colitis
• A Phase 2/3 Safety, Pharmacokinetics, and Efficacy Study ofNirmatrelvir/Ritonavir in Pediatric, Nonhospitalized Symptomatic Participants Wit … Recruiting
  2023-509773-23-00 10 2023-07-13 SARS-CoV-2 Infection
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting
  2024-510635-21-00 5 2023-05-09 warm autoimmune haemolytic anaemia (wAIHA)
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 5 2023-03-17 Diabetic Foot Infections
• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting
  2024-515830-34-00 5 2023-02-14 Congenital antithrombin deficiency
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting
  2022-500367-12-00 5 2022-11-30 Dermatomyositis
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• OPEN LABEL, MAINTENANCE STUDY OF ORAL TOFACITINIB IN CHILDREN WITH MODERATE TO SEVERE ULCERATIVE COLITIS Recruiting
  2023-509694-22-00 5 2022-01-26 Ulcerative Colitis (UC)
• A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor … Recruiting
  2024-515654-25-00 9 2021-12-20 Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Ly
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Recruiting
  2025-523510-87-00 5 2026-06-25 Obesity
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting
  2025-523486-17-00 5 2026-06-16 Obesity

Showing 73–96 of 524 trials